Opti Labs growth treatment, Latisse and Lumigan all contain the same solution of 0.03% bimatoprost.
Lumigan is the name for the original product based on this solution, an eyedrop which treats glaucoma. Glaucoma is a condition affecting the pressure within your eyeball. The treatment was used successfully by millions of patients over a prolonged period.
Glaucoma patients using bimatoprost experiences noticeably longer and thicker eyelashes.
The active ingredient in the treatment, bimatoprost, is a prostaglandin analogue, which has since been found to stimulate the hair growth cycle, resulting in hair that is longer, thicker and darker.
In 2008, the American FDA gave approval for the cosmetic use of bimatoprost 0.03% under the brand name Latisse. The ingredients are the same as Lumigan, as are the concentrations of all the ingredients and the bottle that it is supplied in. The only difference is the packaging and that it is supplied with applicators. There is no other difference between a bottle of Latisse vs Lumigan.
The FDA drew on years of data to compile a safety profile of the treatment. They found that there were significantly fewer side effects when applied to the skin rather than to the eyeball itself. This may be due to the reduced dose, as it’s a smaller area, and because the skin is less sensitive than the eye.
The results were also documented and it was found that the average trial participant grew eyelashes that were 25% longer, 106% thicker and 18% darker.
Latisse is only available in the US. The same 0.03% bimatoprost solution was made available in the UK by Dr Tom Walker and is sold by Opti Laboratories. Over almost two decades, Dr Walker has helped thousands of clients to successfully grow their lashes.
Opti Labs are proud to be a doctor-led brand and to put the health and wellbeing of our clients first.
